RecombiMAb anti-mouse VEGFR-2

产品名称

RecombiMAb anti-mouse VEGFR-2 / 欣博盛生物

产品货号

CP132

产品规格

1/5/25/50/100mg

反应种属

Mouse

克隆号

DC101-CP132

同种型

Mouse IgG2a(switched from rat IgG1)

免疫原

Mouse VEGFR-2-SEAPs soluble receptor

实验应用

in vivo?blocking of VEGF/VEGFR-2 signaling*
in vitro?blocking of VEGFR signaling*
Western blot*
*Reported for the original rat IgG1 DC101 antibody

产品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

纯度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

无菌处理

0.2 μm filtration

纯化方式

Protein G

分子量

150 kDa

小鼠病原检测

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存条件

抗体原液保存在4°C，不能冷冻保存。

推荐同型对照

InVivoPlus mouse IgG2a isotype control, unknown specificity（货号BP0085）

推荐抗体稀释液

InVivoPure pH 7.0 Dilution Buffer（货号IP0070）

应用

文章

体内VEGF/VEGFR-2

信号阻断

(in vivo blocking of?

VEGF/VEGFR-2 signaling)

1.?Ding, X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived?

VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343.

2.?Lee, H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and?

hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma?

mouse models through destruction of tumor vasculature' Int J Radiat Oncol Biol?

Phys 91(3): 621-630.

3.?Arulanandam, R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1?

Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell?

28(2): 210-224.

4.?Kizhatil, K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination?

of blood vascular and lymphatic phenotypes that forms by a novel developmental?

process' PLoS Biol 12(7): e1001912.

体内VEGF/VEGFR-2信号阻断，

体外VEGFR信号阻断

(in vivo blocking of VEGF/VEGFR-2?

signaling, in vitro blocking of VEGFR?

signaling)

1.Larrayoz, M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to?

antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4): 539-550. ?